22 results on '"Smit, E F"'
Search Results
2. DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach
3. VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
4. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
5. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
6. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
7. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy
8. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
9. DNA topoisomerase IIα and -β expression in human ovarian cancer
10. VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
11. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
12. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.
13. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
14. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
15. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
16. A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.
17. A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
18. Acute and cumulative effects of carboplatin on renal function.
19. Phase I study of 21 days continuous infusion with vindesine.
20. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.
21. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
22. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.